Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Javier Szwarcberg | $610,000 | $503,250 | $1,750,518 | $41,805 | $0 | $0 | $5,000 | $2,910,573 |
| Chief Executive Officer | ||||||||
| Samir Gharib | 465,100 | 313,943 | 671,916 | 17,252 | 0 | 0 | 5,000 | 1,473,211 |
| President and Chief Financial Officer | ||||||||
| Kirk Ways | 0 | 0 | 442,050 | 5,529 | 0 | 0 | 596,833 | 1,044,412 |
| Interim Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Javier Szwarcberg | $2,910,573 | — | — | — |
| Samir Gharib | 1,473,211 | — | — | — |
| Kirk Ways | 1,044,412 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Samir Gharib | RSU | 2025-12-11 | — | — | 7,600 | — | — |
| Javier Szwarcberg | RSU | 2025-12-11 | — | — | 19,800 | — | — |
| Kirk Ways | RSU | 2025-12-11 | — | — | 5,000 | — | — |
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Javier Szwarcberg | RSU | 14,850 | — | $1,293,584 |
| Javier Szwarcberg | RSU | 9,791 | — | 852,894 |
| Samir Gharib | RSU | 5,700 | — | 496,527 |
| Kirk Ways | RSU | 3,750 | — | 326,663 |
| Javier Szwarcberg | RSU | 3,588 | — | 312,551 |
| Javier Szwarcberg | RSU | 2,392 | — | 208,367 |
| Samir Gharib | RSU | 1,933 | — | 167,561 |
| Javier Szwarcberg | RSU | 1,666 | — | 145,125 |
| Samir Gharib | RSU | 1,579 | — | 136,875 |
| Samir Gharib | RSU | 1,539 | — | 134,062 |
| Javier Szwarcberg | RSU | 1,480 | — | 128,293 |
| Samir Gharib | RSU | 1,026 | — | 89,375 |
| Samir Gharib | RSU | 953 | — | 82,610 |
| Samir Gharib | RSU | 913 | — | 79,143 |
| Samir Gharib | RSU | 733 | — | 63,540 |
| Samir Gharib | RSU | 496 | — | 43,207 |
| Kirk Ways | RSU | 400 | — | 34,674 |
| Kirk Ways | RSU | 266 | — | 23,058 |
| Kirk Ways | Option | 400 | 9.26 | — |
The Compensation Committee uses its judgment to establish a total compensation program for each named executive officer that is a mix of current, short-term, and long-term incentive compensation, and cash and non-cash compensation, that it believes appropriate to achieve the goals of our executive compensation program and our corporate objectives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Consulting, Inc. |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-21 | 187,027 | 111,274 | 1,573 | 62.7% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-21 | 62.7%a |
a. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 11,000 / 10,000 |
| Stock ownership guideline | — |
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Spruce Biosciences | 2025 | Javier Szwarcberg | $610,000 | $1,750,518 | $41,805 | $0 | $2,910,573 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Javier Szwarcberg | DEF 14A | 2026-04-09 | 0001193125-26-149821 | Section “Executive Compensation”. As printed: 2,910,573. Filing ↗machine: r2 · c8 · span 441735–441744 |
| 2 | Section 01, Samir Gharib | DEF 14A | 2026-04-09 | 0001193125-26-149821 | Section “Executive Compensation”. As printed: 1,473,211. Filing ↗machine: r4 · c8 · span 448000–448009 |
| 3 | Section 01, Kirk Ways | DEF 14A | 2026-04-09 | 0001193125-26-149821 | Section “Executive Compensation”. As printed: 1,044,412. Filing ↗machine: r6 · c8 · span 454691–454700 |
| 4 | Section 03, Samir Gharib RSU | DEF 14A | 2026-04-09 | 0001193125-26-149821 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 478399–478404 |
| 5 | Section 03, Javier Szwarcberg RSU | DEF 14A | 2026-04-09 | 0001193125-26-149821 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 478391–478397 |
| 6 | Section 03, Kirk Ways RSU | DEF 14A | 2026-04-09 | 0001193125-26-149821 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 7 | Section 06, 2026 vote | Form 8-K | 2026-05-26 | 0001193125-26-239230 | Item 5.07 · say-on-pay result. As reported: 62.7% (votes for as printed: 187,027). Filing ↗ |
| 8 | Spruce Biosciences (subject), Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149821 | CEO total compensation as printed in Spruce Biosciences's own proxy. As printed: 2,910,573. Filing ↗machine: r2 · c8 · span 441735–441744 |